Related Experiment Videos
Transcatheter hepatic arterial therapy for symptomatic liver malignancy
C M Guthrie1, A L Leahy, D N Redhead
1University Department of Surgery, Royal Infirmary, Edinburgh, UK.
Journal of the Royal College of Surgeons of Edinburgh
|December 1, 1991
Summary
Transcatheter hepatic arterial chemoembolization (TACE) effectively managed symptoms in most patients with liver cancer. While TACE did not shrink tumors, it improved quality of life for many, showing benefits in tumor vascularity or necrosis.
Area of Science:
- Interventional Radiology
- Oncology
- Hepatology
Background:
- Unresectable liver malignancy presents significant treatment challenges.
- Symptomatic relief is a crucial aspect of palliative care in advanced cancer.
Purpose of the Study:
- To evaluate the efficacy of transcatheter hepatic arterial chemoembolization (TACE) in managing symptoms of unresectable liver malignancy.
- To assess the impact of TACE on patient survival and tumor response.
Main Methods:
- Transcatheter hepatic arterial chemoembolization (TACE) was performed in ten patients.
- Patient-reported symptoms and survival were monitored post-procedure.
- Tumor size, vasculature, and necrosis were assessed via imaging review.
Main Results:
- Nine out of ten patients experienced symptom control for 52-100% of their survival duration.
- One patient died 10 days post-procedure.
- No objective decrease in tumor size was observed; however, three patients showed reduced tumor vasculature or necrosis.
Conclusions:
- TACE offers significant symptomatic benefit for patients with unresectable liver malignancy.
- While not curative, TACE can improve quality of life by managing cancer-related symptoms.
- TACE may induce localized tumor changes such as vascular reduction or necrosis.